ReviewBiomedicines2022
Putative Complementary Compounds to Counteract Insulin-Resistance in PCOS Patients.
Review in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 13 citations in OpenAlex.
- Efficacy Of Combined Nutritional And Pharmacological Interventions In PCOS: A Six Month Randomized Controlled Trial.Naunyn-Schmiedeberg's archives of pharmacology · 2026Trial
- Neutrophil-to-lymphocyte and monocyte-to-lymphocyte ratios as inflammatory markers in the assessment of glycemic status in diabetic patients of Asir region.Animal models and experimental medicine · 2025Article
- Supervised model based polycystic ovarian syndrome detection in relation to vitamin d deficiency by exploring different feature selection techniques.Scientific reports · 2025Article
- PCOS and Obesity: Contraception Challenges.Open access journal of contraception · 2025Review
- To explore the relationship between endometrial hyperemia and polycystic ovary syndrome.Open life sciences · 2025Article
- Research progress of gut microbiota and its metabolites in polycystic ovary syndrome.Frontiers in endocrinology · 2025Review
- Arachidonic acid inhibit granulosa cell function by affecting metabolic function of liver in brown adipose transplantation rats.Journal of ovarian research · 2024Article
- Molecular Research on Polycystic Ovary Syndrome (PCOS).Biomedicines · 2023Article
- Gut microbiota dysbiosis in polycystic ovary syndrome: Mechanisms of progression and clinical applications.Frontiers in cellular and infection microbiology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polycystic ovary syndrome (PCOS) is the most frequent endocrine-metabolic disorder among women at reproductive age. The diagnosis is based on the presence of at least two out of three criteria of the Rotterdam criteria (2003). In the last decades, the dysmetabolic aspect of insulin resistance and compensatory hyperinsulinemia have been taken into account as the additional key features in the etiopathology of PCOS, and they have been widely studied. Since PCOS is a complex and multifactorial syndrome with different clinical manifestations, it is difficult to find the gold standard treatment. Therefore, a great variety of integrative treatments have been reported to counteract insulin resistance. PCOS patients need a tailored therapeutic strategy, according to the patient's BMI, the presence or absence of familiar predisposition to diabetes, and the patient's desire to achieve pregnancy or not. The present review analyzes and discloses the main clinical insight of such complementary substances.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.